• Skip to main content
  • Skip to footer

Accuronix

Developing novel cancer therapies

  • Home
  • Founders
  • Approach
  • Contact

January 27, 2016

St. Louis Post-Dispatch

BioGenerator and the state-funded Missouri Technology Corp. have invested in a cancer-drug startup that’s based on Washington University research.

The startup, Accuronix Therapeutics, raised a total of $625,000, with BioGenerator as the lead investor. Accuronix is developing drugs for difficult-to-treat forms of cancer, starting with pancreatic cancer.

Read more

Filed Under: News

Footer

About Us

We are applying a novel drug-targeting technology to some of the most difficult problems in cancer therapy.

News & Publications
Financial Conflicts of Interest (FCOI)

Mission

With an initial focus in pancreatic cancer, the Company’s mission is to develop novel oncology therapies based on technology that selectively targets σ-2 receptors overexpressed on cancer cells

Partners

Washington University | University of Pennsylvania | BioGenerator

Contact Us

Accuronix Therapeutics
4340 Duncan Ave.
Suite 210
St. Louis, MO 63110

Contact
Bradley T. Keller, Ph.D.
President and CEO
[email protected]

Copyright © 2025 Accuronix.com · Powered by NeuConcept